Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 08h00 HE
|
Chiasma
NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the...
Chiasma to Report Fourth Quarter 2020 Results on March 4
25 févr. 2021 08h00 HE
|
Chiasma
NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
Chiasma Announces Hiring of John Doyle as Chief Financial Officer
19 janv. 2021 07h00 HE
|
Chiasma
NEEDHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
Chiasma Provides Corporate Update and Previews Expected 2021 Milestones
06 janv. 2021 16h01 HE
|
Chiasma
MYCAPSSA® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA® EMA submission for EU marketing approval on track for mid-2021 following positive results of...
Chiasma to Participate in Two Investor Conferences in December
23 nov. 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results
20 nov. 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial Comparing MYCAPSSA® (octreotide capsules) to Long Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
18 nov. 2020 07h00 HE
|
Chiasma
91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlled phase of the non-inferiority trial Company intends to submit a marketing application for MYCAPSSA in the EU...
Chiasma to Participate in the Jefferies Virtual London Healthcare Conference
16 nov. 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update
05 nov. 2020 16h05 HE
|
Chiasma
Launched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September Well capitalized to support the MYCAPSSA launch On track to announce MPOWERED™ Phase 3 trial...
Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day
30 oct. 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to...